The competitive landscape of ANDA litigation has played a significant role in shaping the pharmaceutical industry, showcasing the legal experts who make a substantial impact in this field. Attorneys specializing in ANDA cases are pivotal in protecting the intellectual property of brand-name pharmaceutical companies and defending generic manufacturers seeking market... Read More

In the pharmaceutical industry, innovation drives progress, but intense legal battles, particularly in ANDA (Abbreviated New Drug Application) litigation, shape the competitive landscape. Our recently released 2024 ANDA Litigation Intelligence Report provides an in-depth analysis of the key players in this sector, shedding light on the top pharmaceutical companies driving... Read More

When several ANDA filers seek approval for the same drug, a branded pharmaceutical company may struggle to bring Hatch-Waxman Act patent infringement lawsuits against all challengers in a single court due to venue limitations. In recent years, multidistrict litigations (MDLs) have become a tool for companies to consolidate these cases... Read More

Revlimid (lenalidomide), developed by Celgene Corporation, has been a groundbreaking treatment for multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma since its FDA approval in 2005. The drug has also been at the center of complex legal battles involving patent litigation and antitrust cases. From 2009 to 2018, Celgene reported... Read More

The landscape of patent litigation has seen significant shifts over the past five years, and the first half of 2024 makes no exception presenting notable trends and developments. In particular, Q2 has marked an increase of 16% in patent litigation compared to the previous quarter. This article provides insights into... Read More